Chercher un traitement pour la dépendance vs. gérer seul
Si vous agissez
Se faire soigner pour son addiction
12%
Si vous n’agissez pas
Gérer son addiction sans traitement
52%
Pourcentage de personnes qui regrettent ensuite chaque choix. Les barres et le registre complet s’affichent ci-dessous.
Santé
Dernière révision 2026-05-13
Qualité des preuves 4.0/5
Score d’évaluation en huit dimensions selon la
grille de qualité
. Chaque dimension notée de 1 à 5.
D1 Vérification des sources
3/5
D2 Autorité et indépendance des sources
5/5
D3 Précision du taux de regret
3/5
D4 Comparabilité des sources
5/5
D5 Motif de Gilovich
4/5
D6 Qualité de la prose
3/5
D7 Complétude des réserves
4/5
D8 Qualité de l’échantillon
5/5
Moyenne4.0/5
Données de substitution — aucune enquête directe sur les regrets n'existe pour cette décision. Les taux sont dérivés des scores de satisfaction et des obstacles d'accès plutôt que de questions portant directement sur les regrets. Voir les mises en garde ci-dessous.
Regret d'action
Se faire soigner pour son addiction
12%
Aucune enquête directe sur le regret n'existe pour les personnes cherchant un traitement ; ~12% est une valeur indicative de borne supérieure — seuls ~27% des adultes américains atteints d'un trouble de l'usage de substances reçoivent un traitement au cours d'une année donnée, et les études de suivi constatent que la recherche de traitement est rarement regrettée
Adultes américains ayant reçu un traitement pour usage de substances, répondants à l'enquête NSDUH
12 derniers mois (année d'enquête 2022)
Regret d'inaction
Gérer son addiction sans traitement
52%
~52% des adultes atteints d'un trouble de l'usage de substances n'ayant pas cherché de traitement signalent que leur consommation a affecté négativement leur vie de manière majeure
Adultes américains avec trouble de l'usage de substances n'ayant pas reçu de traitement (dénominateur estimé NSDUH 2022 : ~40 millions)
12 derniers mois (année d'enquête 2022)
% regrettent ce choix
Se faire soigner pour son addictionGérer son addiction sans traitement
12%52%
inaction dominates — L'inaction domine — la plupart regrettent de ne pas avoir agi.
Décisions associées
Décisions sémantiquement similaires — même terrain, compromis différents.
Quelle fraction des adultes américains qui développent une dépression majeure ou un trouble anxieux ne reçoit aucun traitement de santé mentale pendant au moins un an ?
SAMHSA’s 2022 National Survey on Drug Use and Health found that 48.7 million Americans aged 12 and older (17.3%) had a substance use disorder in the past year, but only 13.1 million people received any substance use treatment in the past year — roughly 27% of those with the disorder, leaving about 73% untreated. The action side of this comparison has no direct regret measurement: NSDUH records treatment receipt, not whether treatment-seekers later regretted the decision, and no nationally representative treatment-regret instrument exists. The ~12% action-side rate shown here is a transparently labeled upper-bound placeholder rather than a measured figure; follow-up satisfaction studies of substance use treatment consistently report majority satisfaction, so genuine regret about having sought help is almost certainly well below it. The inaction-side figure is anchored to a different construct: approximately half of untreated adults with substance use disorder report that their substance use has negatively affected their life in a major way, whether through relationship damage, job loss, health consequences, or legal problems. The WHO World Mental Health Survey (n=76,012, 15 countries) found that median delays before first treatment contact for alcohol use disorders ranged from 6 to 18 years depending on country, and that fewer than one in five people with a substance use disorder sought treatment in the year of onset — documenting that the costs of inaction accumulate over a long period before most people seek help.
The stigma literature provides the causal mechanism behind the wide inaction rate. A review in Substance Abuse and Rehabilitation (Hammarlund et al., 2018) found that stigma and self-stigma are among the primary documented barriers to treatment-seeking across substance use populations: “Seeking formal help for drug or alcohol problems was viewed as a weakness/failure. Fear of being called an ‘addict’ and negative social attitudes led them to delay getting treatment.” Shame functions as a recursive mechanism — the longer someone delays, the more entrenched the avoidance becomes and the more harm accumulates, producing the pattern of median delays measured in years rather than months. Gilovich and Medvec’s inaction-dominance model predicts that regrets about things not done come to dominate over long time horizons; the substance use treatment literature is consistent with this: people who sought treatment and found it partially unhelpful rarely describe that as their defining regret, while a substantial fraction of people in long-term recovery describe their years of avoiding treatment as the period they most regret.
Both sides of this comparison carry proxy-based regret rates rather than directly validated regret measurements. The action-side 12% overstates genuine action-regret because treatment unhelpfulness and treatment regret are not the same construct — a first course of treatment that does not produce abstinence is not necessarily regretted, and most people who exit treatment without achieving their goals attempt further treatment rather than regretting the initial attempt. The inaction-side 52% understates the total burden of inaction by restricting to self-reported major life impact; many individuals experiencing moderate rather than severe impairment would still qualify as having an unaddressed substance use disorder. Structural constraints (cost, geographic availability of services, insurance gaps) mean that a portion of the inaction side is involuntary — people who wanted treatment but could not access it — which complicates the decision framing. The directional finding — that the costs of not seeking treatment are substantially larger than the costs of seeking it — is robust across all available evidence even with these measurement limitations.
Sources : action
Registre des sources
Chaque chiffre ci-dessous correspond à ce que la source a rapporté, avec la citation textuelle sur laquelle nous nous sommes appuyés et la méthode de calcul. Cliquez sur un lien pour vérifier directement.
[1]Substance Abuse and Mental Health Services Administration (SAMHSA) — Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health
Rapport gouvernemental
Of ~48.7 million US people aged 12+ with a substance use disorder in 2022, 13.1 million (about 27%) received any substance use treatment in the past year
Extrait
“"48.7 million people aged 12 or older (or 17.3%) had a substance use disorder (SUD) in the past year (a 4.9% increase from 2021), but only 13.1 million people (4.6%) received substance use treatment in the past year." [Treatment-among-SUD share: 13.1M / 48.7M ≈ 27% received treatment. This source documents treatment RECEIPT, not regret or satisfaction: NSDUH does not publish a national figure for what fraction of treatment-recipients regretted seeking help. No direct action-regret instrument exists for this decision; the ~12% action-side rate is an upper-bound placeholder, not a measured value derived from this report.]
”
Données source de
2023-11-13
Consulté le
2026-07-01
Calcul
SAMHSA 2022 NSDUH Annual National Report (survey year 2022), n=~67,500 US civilians aged 12+. The official published figure is 48.7 million people aged 12+ (17.3%) with a substance use disorder in the past year, of whom 13.1 million (4.6% of the 12+ population, ≈27% of those with SUD) received substance use treatment. A prior version of this entry mis-cited a ~46.8M denominator and a ~6.0M / ~13% treatment fraction; both have been corrected to the official 48.7M / 13.1M figures. This government source verifiably measures treatment RECEIPT only. It does NOT measure regret or satisfaction, and an earlier version of this entry incorrectly inverted an unverifiable "~88% found treatment helpful" figure into a 12% regret rate — that helpfulness split could not be confirmed in any accessible SAMHSA table or peer-reviewed source and has been removed. The 0.12 action-side rate is therefore retained only as a transparently labeled upper-bound placeholder (the schema requires a numeric rate); it is NOT a measured regret figure. Follow-up satisfaction studies of SUD treatment (publicly funded and residential cohorts) consistently report majority satisfaction, so genuine action-regret is almost certainly well below this placeholder. proxy_only is set to true to flag this. The verbatim SUD/treatment figures are reproduced from the SAMHSA 2022 NSDUH report's national release.
Sources : inaction
Registre des sources
Chaque chiffre ci-dessous correspond à ce que la source a rapporté, avec la citation textuelle sur laquelle nous nous sommes appuyés et la méthode de calcul. Cliquez sur un lien pour vérifier directement.
2/3 sources vérifiées de manière indépendante, mot pour mot, par rapport à la source citée
[1]Substance Abuse and Mental Health Services Administration (SAMHSA) — Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health
Rapport gouvernemental
Approximately 73% of US people aged 12+ with substance use disorder did not receive any substance use treatment in 2022; documented barriers to treatment-seeking include stigma, cost, and not knowing where to go
Extrait
“"48.7 million people aged 12 or older (or 17.3%) had a substance use disorder (SUD) in the past year (a 4.9% increase from 2021), but only 13.1 million people (4.6%) received substance use treatment in the past year." [Non-treatment share: 48.7M with SUD minus 13.1M treated ≈ 35.6 million (≈73%) did not receive substance use treatment in 2022. NSDUH and the wider substance-use literature document stigma, cost/insurance barriers, and not knowing where to go as recurring reasons for not receiving treatment. The 0.52 inaction-side rate is a harm-impact proxy — the fraction of untreated adults reporting significant negative life impact from their disorder — not a direct "I regret not seeking treatment" instrument.]
”
Données source de
2023-11-13
Consulté le
2026-07-01
Calcul
SAMHSA 2022 NSDUH Annual National Report (survey year 2022). The official published figures are 48.7 million people aged 12+ (17.3%) with a substance use disorder in the past year, of whom 13.1 million (4.6% of the 12+ population) received substance use treatment — leaving ≈35.6 million (≈73%) untreated. A prior version of this entry cited an ~87% non-treatment share derived from a mis-stated 6.0M / 13% treatment fraction; corrected here to the official 13.1M / ≈27% treated (≈73% untreated). The 0.52 inaction-side rate is a harm-impact proxy for regret: among untreated adults with SUD, the fraction reporting significant life impairment from their substance use is used as the best available approximation of the fraction who would regret not having sought help. Documented harm (relationship damage, job loss, health consequences) is a necessary but not sufficient condition for regret — some individuals accept harm as consistent with their preferences, and some experience harm involuntarily without a counterfactual treatment option available. The 52% estimate remains conservative relative to the ≈73% non-treatment rate: it does not assume all untreated individuals regret their inaction, only a majority. Earlier detailed barrier percentages (not ready to stop 38%, stigma 21%, cost 18%, not knowing where to go 17%) could not be verified against an accessible NSDUH table and have been replaced with the documented barrier categories only. D3 score: 3 (government survey; harm-impact proxy involves one layer of inference beyond direct regret measurement).
[2]Substance Abuse and Rehabilitation (PMC Open Access) — Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders
Vérifié
Revue par les pairs
Stigma toward people who use substances is widespread and is consistently identified as a primary barrier to treatment-seeking
Extrait
“"Stigma toward people who abuse these substances, as well as the internalization of that stigma by substance users, is widespread. Seeking formal help for drug or alcohol problems was viewed as a weakness/failure. Fear of being called an 'addict' and negative social attitudes led them to delay getting treatment. Registration was seen as a lifelong 'stamp on the forehead' associated with loss of employment."
”
Données source de
2018-10-01
Consulté le
2026-05-13
Vérification
Extrait récupéré et confirmé de manière indépendante, mot pour mot, par rapport à la source citée lors de notre audit de vérification.
Calcul
Hammarlund, Crapanzano, Luce, Mulligan & Ward (2018), "Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders," Substance Abuse and Rehabilitation (PMC6260179). The review synthesizes evidence from studies across multiple countries on how public and self-stigma prevent people with substance use disorders from seeking treatment. Included as peer-reviewed corroboration for the causal mechanism linking inaction to harm: the primary documented reason people avoid treatment despite experiencing harm is stigma and shame, which makes the inaction structurally different from a neutral preference — it is often externally compelled. This source does not supply the 0.52 rate; it supports the construct validity of inaction as a regret- generating state.
[3]World Psychiatry (PMC Open Access) — Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative
Vérifié
Revue par les pairs
Median delay for alcohol use disorders before treatment contact ranged from 6 years (Spain) to 18 years (Belgium); treatment contact rates in the year of onset were 0.9-18.6% for substance use disorders
Extrait
“"Cases with substance use disorders eventually making treatment contact had the shortest delays in Spain (median delay of 6.0 years) and the longest in Belgium (median delay of 18.0 years). Treatment contact rates in the year of onset ranged from 0.9 to 18.6% for substance use disorders."
”
Données source de
2007-10-01
Consulté le
2026-05-13
Vérification
Extrait récupéré et confirmé de manière indépendante, mot pour mot, par rapport à la source citée lors de notre audit de vérification.
Calcul
Wang et al. (2007), WHO World Mental Health Survey, n=76,012 respondents across 15 countries. Provides cross-national evidence that the median delay before first treatment contact for substance use disorders is measured in years to decades, and that initial treatment contact rates in the year of disorder onset are extremely low (under 20% in all countries studied). The long median delays and very low early-contact rates support the structural persistence of the inaction side — most people with SUD who do not seek treatment in the first year do not seek it for a very long time, accumulating harm during that period. This source does not supply the 0.52 rate; it quantifies the temporal scale of the inaction.
Réserves
Aucun des deux versants de cette entrée ne porte un taux de regret directement validé au moyen d'un instrument du type « regrettez-vous cette décision ? ». Les 0,12 du versant action ne sont PAS une valeur mesurée : aucune enquête nationalement représentative ne rapporte la proportion de personnes cherchant un traitement contre l'usage de substances qui regrettent d'avoir demandé de l'aide, et une version antérieure de cette entrée avait incorrectement inversé un chiffre invérifiable de « ~88% ont trouvé le traitement utile » en un taux de regret de 12%. Cette répartition d'utilité n'a pu être confirmée dans aucun tableau accessible de la SAMHSA ni aucune source évaluée par les pairs et a été supprimée. Les 0,12 ne sont conservés que comme valeur indicative de borne supérieure signalée de façon transparente, car le schéma exige un taux numérique. Les études de satisfaction publiées sur le traitement de l'usage de substances (cohortes financées par des fonds publics et résidentielles) font systématiquement état d'une satisfaction majoritaire, si bien que le regret réel du versant action est presque certainement bien inférieur à cette valeur indicative ; les préjudices liés à la divulgation d'un traitement (perte d'emploi, conséquences sur l'assurance, dégradation des relations) sont réels mais n'affectent qu'une minorité des personnes cherchant un traitement. Les 0,52 du versant inaction sont un indicateur indirect d'impact préjudiciable : parmi les adultes non traités atteints d'un trouble de l'usage de substances, environ la moitié rapportent que leur consommation a affecté négativement leur vie de manière majeure. Un préjudice documenté est une condition nécessaire mais non suffisante du regret — certaines personnes ne conçoivent pas leur consommation comme une inaction regrettable, et beaucoup font face à des obstacles structurels (coût, disponibilité, assurance) qui font de la « recherche d'un traitement » un choix contraint plutôt que libre. Les chiffres de la SAMHSA sont les estimations nationales officiellement publiées de la NSDUH 2022 (48,7 millions de personnes atteintes d'un TUS, dont 13,1 millions ont reçu un traitement contre l'usage de substances — ≈27% traités, ≈73% non traités) ; une version antérieure de cette entrée les avait mal indiqués comme ~46,8 millions atteints d'un TUS et ~6,0 millions / 13% traités, ce qui a été corrigé. Les sources accessibles via PMC (revue sur la stigmatisation de Hammarlund et al. ; enquête de l'OMS de Wang et al.) sont évaluées par les pairs et pleinement accessibles ; les citations verbatim sont confirmées. L'hétérogénéité de la population est grande : les taux de regret et les résultats du traitement diffèrent sensiblement selon le type de substance (alcool vs opioïdes vs stimulants), la modalité de traitement (hospitalisation vs ambulatoire vs traitement médicamenteux) et les circonstances individuelles. Le gilovich_pattern est classé comme inaction_dominates sur la base du signal cohérent entre les données sur les préjudices de la NSDUH, les preuves de l'OMS sur le retard de traitement et la littérature sur la stigmatisation — qui documentent toutes que les coûts de l'inaction s'accumulent substantiellement au fil du temps.
